Catalyst Pharmaceuticals, Inc. (CPRX) experienced robust growth in the first quarter of 2023, primarily propelled by the growth of FIRDAPSE® and the strong revenue stream derived from its newly acquired product, FYCOMPA®.
FIRDAPSE® is an amifampridine phosphate tablet used for treating patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS), while FYCOMPA® is a medication for individuals with epilepsy. In January 2023, CPRX completed the acquisition of U.S. rights for FYCOMPA®.
